These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36495470)

  • 41. Gait characteristics and clinical relevance of hereditary spinocerebellar ataxia on deep learning.
    Jin L; Lv W; Han G; Ni L; Sun D; Hu X; Cai H
    Artif Intell Med; 2020 Mar; 103():101794. PubMed ID: 32143799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intensive coordinative training improves motor performance in degenerative cerebellar disease.
    Ilg W; Synofzik M; Brötz D; Burkard S; Giese MA; Schöls L
    Neurology; 2009 Dec; 73(22):1823-30. PubMed ID: 19864636
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reliability and validity of ICARS in focal cerebellar lesions.
    Schoch B; Regel JP; Frings M; Gerwig M; Maschke M; Neuhäuser M; Timmann D
    Mov Disord; 2007 Nov; 22(15):2162-9. PubMed ID: 17712842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spinocerebellar ataxia types 1, 2, 3 and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings.
    Jacobi H; Hauser TK; Giunti P; Globas C; Bauer P; Schmitz-Hübsch T; Baliko L; Filla A; Mariotti C; Rakowicz M; Charles P; Ribai P; Szymanski S; Infante J; van de Warrenburg BP; Dürr A; Timmann D; Boesch S; Fancellu R; Rola R; Depondt C; Schöls L; Zdzienicka E; Kang JS; Ratzka S; Kremer B; Stephenson DA; Melegh B; Pandolfo M; Tezenas du Montcel S; Borkert J; Schulz JB; Klockgether T
    Cerebellum; 2012 Mar; 11(1):155-66. PubMed ID: 21701895
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Psychometric properties of outcome measures evaluating decline in gait in cerebellar ataxia: A systematic review.
    Milne SC; Murphy A; Georgiou-Karistianis N; Yiu EM; Delatycki MB; Corben LA
    Gait Posture; 2018 Mar; 61():149-162. PubMed ID: 29351857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The interrelationship between disease severity, dynamic stability, and falls in cerebellar ataxia.
    Schniepp R; Schlick C; Pradhan C; Dieterich M; Brandt T; Jahn K; Wuehr M
    J Neurol; 2016 Jul; 263(7):1409-17. PubMed ID: 27159995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.
    Feil K; Adrion C; Teufel J; Bösch S; Claassen J; Giordano I; Hengel H; Jacobi H; Klockgether T; Klopstock T; Nachbauer W; Schöls L; Stendel C; Uslar E; van de Warrenburg B; Berger I; Naumann I; Bayer O; Müller HH; Mansmann U; Strupp M
    BMC Neurol; 2017 Jan; 17(1):7. PubMed ID: 28068987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An atypical case of hypomagnesemia-induced cerebellar syndrome with literature review.
    Wahane M; Kaushal H; Goyal G; Sarna M
    J R Coll Physicians Edinb; 2023 Dec; 53(4):272-277. PubMed ID: 37936278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease.
    DiBenedetti DB; Menne H; Paulsen R; Krasa HB; Vradenburg G; Comer M; Callahan LF; Winfield J; Potashman M; Heithoff K; Hartry A; Oberdhan D; Wilson H; Hoffman DL; Wieberg D; Kremer IN; Taylor GA; Taylor JM; Lappin D; Martin AD; Hauber B; Romano C
    Neurol Ther; 2023 Apr; 12(2):571-595. PubMed ID: 36790638
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comprehensive scheme for the objective upper body assessments of subjects with cerebellar ataxia.
    Tran H; Nguyen KD; Pathirana PN; Horne MK; Power L; Szmulewicz DJ
    J Neuroeng Rehabil; 2020 Dec; 17(1):162. PubMed ID: 33276783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study.
    Bier JC; Dethy S; Hildebrand J; Jacquy J; Manto M; Martin JJ; Seeldrayers P
    J Neurol; 2003 Jun; 250(6):693-7. PubMed ID: 12796831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurodegenerative Cerebellar Ataxia.
    Rosenthal LS
    Continuum (Minneap Minn); 2022 Oct; 28(5):1409-1434. PubMed ID: 36222772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Italian cross-cultural adaptation of the patient-reported outcome measure of ataxia.
    Castaldo A; Farinotti M; Fichera M; Nanetti L; Fortuna F; Mariotti C; Solari A
    Neurol Sci; 2023 Aug; 44(8):2773-2779. PubMed ID: 36869274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inter-rater reliability and validity of two ataxia rating scales in children with brain tumours.
    Hartley H; Pizer B; Lane S; Sneade C; Pratt R; Bishop A; Kumar R
    Childs Nerv Syst; 2015 May; 31(5):693-7. PubMed ID: 25735848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitative evaluation of gait ataxia by accelerometers.
    Shirai S; Yabe I; Matsushima M; Ito YM; Yoneyama M; Sasaki H
    J Neurol Sci; 2015 Nov; 358(1-2):253-8. PubMed ID: 26362336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Applicability of quantitative oculomotor and SARA assessment in children.
    Vogelaar FA; Brandsma R; Maurits NM; Sival DA
    Eur J Paediatr Neurol; 2021 Nov; 35():56-60. PubMed ID: 34610562
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative analysis of upper-limb ataxia in patients with spinocerebellar degeneration.
    Ueda N; Hakii Y; Koyano S; Higashiyama Y; Joki H; Baba Y; Suzuki Y; Kuroiwa Y; Tanaka F
    J Neurol; 2014 Jul; 261(7):1381-6. PubMed ID: 24781836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.
    Feil K; Adrion C; Boesch S; Doss S; Giordano I; Hengel H; Jacobi H; Klockgether T; Klopstock T; Nachbauer W; Schöls L; Steiner KM; Stendel C; Timmann D; Naumann I; Mansmann U; Strupp M;
    JAMA Netw Open; 2021 Dec; 4(12):e2135841. PubMed ID: 34905009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal tracking of gait and balance impairments in cerebellar disease.
    Morton SM; Tseng YW; Zackowski KM; Daline JR; Bastian AJ
    Mov Disord; 2010 Sep; 25(12):1944-52. PubMed ID: 20544808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales.
    Bürk K; Schulz SR; Schulz JB
    J Neurochem; 2013 Aug; 126 Suppl 1():118-24. PubMed ID: 23859347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.